Open AccessAdvances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases
Author(s) -
Ankur Sharma,
Dhruv Kumar,
Kajal Dahiya,
Susan Hawthorne,
Saurabh Kumar Jha,
Niraj Kumar Jha,
Parma Nand,
Samuel Girgis,
Sibi Raj,
Rashi Srivastava,
Vineet Kumar Goswami,
Yiota Gregoriou,
Sally A. ElZahaby,
Shreesh Ojha,
Harish Dureja,
Gaurav Gupta,
Sachin Kumar Singh,
Dinesh Kumar Chellappan,
Kamal Dua
Publication year - 2021
Publication title -
nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 109
eISSN - 1748-6963
pISSN - 1743-5889
DOI - 10.2217/nnm-2021-0057
Subject(s) - biofilm , nanocarriers , intensive care medicine , drug delivery , medicine , therapeutic modalities , drug , treatment modality , respiratory system , biology , nanotechnology , pharmacology , bacteria , materials science , genetics
The increasing burden of respiratory diseases caused by microbial infections poses an immense threat to global health. This review focuses on the various types of biofilms that affect the respiratory system and cause pulmonary infections, specifically bacterial biofilms. The article also sheds light on the current strategies employed for the treatment of such pulmonary infection-causing biofilms. The potential of nanocarriers as an effective treatment modality for pulmonary infections is discussed, along with the challenges faced during treatment and the measures that may be implemented to overcome these. Understanding the primary approaches of treatment against biofilm infection and applications of drug-delivery systems that employ nanoparticle-based approaches in the disruption of biofilms are of utmost interest which may guide scientists to explore the vistas of biofilm research while determining suitable treatment modalities for pulmonary respiratory infections.